Saturday 17 October 2026
Export NKTR’s income statement to Excel — free account
Nektar Therapeutics
NKTR Healthcare Biotechnology
Nektar Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $55.2 million, down 43.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.34%, EPS grew 58.3% and free cash flow fell 65.7%, each against the same quarter a year earlier.
35.78
1.94
−5.14%
Follow NKTR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 3 | 4 | 2 | 5 | 2 | 8 | 5 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.35 | 0.00 | 0.00 |
P/S ratio |
12.91 | 1.94 | 1.24 | 4.45 | 24.31 | 19.86 | 32.98 | 4.67 | 29.23 | 10.71 |
Altman Z-Score |
(17.07) | (16.13) | (13.11) | (6.38) | (0.62) | 1.83 | 2.62 | 9.18 | 8.31 | (2.45) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.89 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(41.60) | (36.33) | (27.81) | (12.71) | (5.15) | 0.06 | 1.55 | 8.30 | (10.65) | (8.64) |
P/Operating CF |
(10.98) | (4.14) | (2.38) | (7.11) | (16.35) | (30.79) | (30.19) | (47.45) | (111.88) | (33.82) |
Beneish M-Score |
— | — | (4.39) | (3.82) | (3.39) | (2.73) | 2.35 | 1.54 | (2.27) | (3.04) |
P/B ratio |
7.94 | 3.15 | 0.86 | 1.12 | 3.65 | 2.82 | 2.69 | 3.25 | 102.42 | 20.11 |
Price to Tangible BV |
8.42 | 0.00 | 2.06 | 1.41 | 4.11 | 3.04 | 2.84 | 3.40 | 794.14 | 152.48 |
EV/Sales |
17.56 | 4.45 | 3.45 | 4.43 | 22.04 | 16.20 | 25.79 | 3.87 | 29.47 | 10.59 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.60 | 0.00 | 0.00 |
EV/Operating CF |
(4.65) | (2.50) | (1.61) | (1.34) | (5.44) | (7.91) | (8.99) | 6.42 | (112.78) | (14.97) |
EV/FCF |
(4.65) | (2.47) | (1.62) | (1.37) | (5.25) | (7.73) | (8.33) | 6.53 | (100.67) | (14.19) |
Quick Ratio |
4.59 | 4.16 | 5.95 | 7.49 | 8.88 | 9.51 | 3.85 | 16.81 | 5.36 | 5.60 |
Current Ratio |
4.97 | 4.26 | 6.45 | 8.00 | 9.34 | 9.83 | 4.02 | 17.53 | 5.82 | 5.90 |
Net Debt/EBITDA |
1.77 | 2.53 | 1.69 | 1.39 | 1.70 | 2.58 | 2.45 | (1.56) | 1.13 | 1.46 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 12.79% | 11.49% | 48.19% | 43.33% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.14 | 2.79 | 2.80 |
Asset Turnover |
0.19 | 0.28 | 0.16 | 0.10 | 0.08 | 0.09 | 0.06 | 0.90 | 0.57 | 0.31 |
Operating CF/Net income |
1.27 | 1.48 | 0.70 | 0.83 | 0.79 | 0.70 | 0.75 | 1.05 | 0.83 | 0.76 |
Capex/Depreciation |
(0.17) | (0.33) | 0.00 | 0.58 | (1.06) | (0.51) | (14.92) | (1.07) | (0.66) | (0.42) |
Interest Coverage |
(5.35) | (3.74) | (10.41) | (13.01) | (9.43) | (11.45) | (9.49) | 16.08 | (1.46) | (2.68) |
| (217.94%) | (124.10%) | (110.95%) | (70.39%) | (59.64%) | (35.80%) | (28.22%) | 75.47% | (109.91%) | (324.73%) | |
| (56.17%) | (33.90%) | (49.80%) | (40.29%) | (39.45%) | (25.28%) | (21.35%) | 51.25% | (17.94%) | (28.76%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,725.40%) | (82.49%) | 68.34% | (101.01%) | 0.00% |
Return on Tangible Assets |
(76.39%) | (58.51%) | (92.55%) | (72.17%) | (67.95%) | (41.08%) | (38.88%) | 48.51% | (30.39%) | (36.61%) |
Average Days of Receivables |
0.00 | 0.00 | 4.88 | 23.71 | 80.56 | 92.83 | 117.20 | 13.22 | 5.95 | 34.59 |
Research and Development Expense of Revenue |
212.43% | 122.84% | 126.67% | 237.17% | 392.78% | 267.26% | 379.15% | 33.48% | 87.24% | 123.19% |
Selling, General and Administrative Expense of Revenue |
124.34% | 77.98% | 85.90% | 100.30% | 120.55% | 68.46% | 86.12% | 6.82% | 17.02% | 26.76% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.11 | 0.07 | 0.05 | 0.04 | 0.04 | 0.15 | 0.13 |
Share Based Compensation of Revenue |
22.90% | 21.96% | 37.05% | 62.27% | 92.90% | 61.64% | 87.07% | 7.38% | 11.90% | 15.63% |
Graham Net Nets |
0.11 | 0.10 | 0.57 | 0.49 | 0.14 | 0.22 | 0.22 | 0.18 | (0.01) | (0.03) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 449.22 | 0.00 | 0.00 |
Earnings Yield |
(24.12%) | (63.41%) | (247.34%) | (89.91%) | (21.16%) | (14.64%) | (11.62%) | 11.98% | (1.09%) | (8.66%) |
Free Cash Flow Yield |
(29.26%) | (92.63%) | (171.39%) | (72.31%) | (17.26%) | (10.55%) | (9.39%) | 12.67% | (1.00%) | (6.96%) |
Revenue per Share |
3.27 | 7.18 | 7.11 | 7.38 | 8.34 | 12.84 | 9.82 | 105.49 | 29.58 | 17.77 |
Operating CF per Share |
(12.36) | (12.82) | (15.20) | (24.36) | (33.75) | (26.30) | (28.16) | 63.49 | (7.73) | (12.57) |
Capex per Share |
(0.01) | (0.11) | 0.03 | 0.60 | (1.23) | (0.61) | (2.25) | (1.03) | (0.93) | (0.69) |
Free Cash Flow per Share |
(12.37) | (12.92) | (15.17) | (23.75) | (34.98) | (26.91) | (30.41) | 62.46 | (8.66) | (13.25) |
Cash per Share |
14.57 | 18.61 | 23.96 | 40.46 | 60.03 | 89.15 | 113.51 | 118.04 | 28.47 | 41.79 |
Shareholders Equity per Share |
5.32 | 4.43 | 10.34 | 29.37 | 55.58 | 90.44 | 120.41 | 151.83 | 8.44 | 9.46 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.32 | 4.43 | 10.34 | 29.37 | 55.58 | 90.44 | 120.41 | 151.83 | 8.44 | 9.46 |
Free Cash Flow |
(208.68) | (177.18) | (192.23) | (296.49) | (427.65) | (320.54) | (354.97) | 706.61 | (90.09) | (123.42) |
Working Capital |
212.73 | 199.89 | 279.43 | 477.76 | 710.38 | 1,022.23 | 1,067.66 | 1,355.69 | 270.66 | 353.73 |
Capital Expenditures |
(0.17) | (1.47) | 0.38 | 7.52 | (14.99) | (7.26) | (26.28) | (11.61) | (9.68) | (6.39) |
Net Current Asset Value |
75.69 | 18.18 | 63.66 | 202.01 | 357.90 | 676.53 | 849.59 | 1,005.09 | (94.22) | (54.79) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.71 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.01 | 0.00 | (0.08) | 0.15 | 0.05 | 0.23 | 0.01 | 0.03 | 0.04 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.11 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.50 | 1.29 | 4.47 | 0.40 | 0.23 | 0.24 | 0.03 | 0.22 | 0.31 | 0.23 |
Cash ROIC |
(62.18%) | (56.08%) | (44.23%) | (34.02%) | (30.26%) | (14.98%) | (11.90%) | 21.41% | (14.32%) | (17.05%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 25.08 | 6.47 | 3.32 | 4.04 | 2.86 | 49.49 | 29.74 | 9.29 |
Accounts Payable Turnover |
0.00 | 2.87 | 2.96 | 1.90 | 1.56 | 0.94 | 1.70 | 4.59 | 8.04 | 11.67 |
Inventory Turnover |
— | 0.00 | 1.91 | 1.24 | 1.60 | 1.39 | 1.78 | 2.21 | 2.80 | 2.69 |
Average Days of Payables |
0.00 | 137.50 | 106.45 | 218.98 | 142.89 | 414.89 | 328.46 | 87.53 | 57.14 | 34.02 |
Days of Inventory on Hand |
— | 0.00 | 174.04 | 323.95 | 231.65 | 286.57 | 216.28 | 170.16 | 128.16 | 134.20 |
Average Receivables |
— | — | 3.59 | 14.24 | 30.69 | 37.85 | 40.01 | 24.11 | 10.35 | 17.81 |
Average Payables |
11.17 | 10.70 | 11.41 | 11.36 | 15.94 | 20.69 | 12.54 | 5.32 | 3.80 | 2.59 |
Average Inventory |
— | — | 17.65 | 17.50 | 15.55 | 13.98 | 12.02 | 11.05 | 10.92 | 11.23 |
Average Assets |
292.13 | 350.94 | 554.32 | 913.89 | 1,327.98 | 1,758.06 | 2,063.76 | 1,329.52 | 538.87 | 533.76 |
Average Common Equity |
75.28 | 95.86 | 248.81 | 523.07 | 878.40 | 1,241.34 | 1,561.48 | 902.70 | 87.98 | 47.28 |
Columns are period end dates